Recent advances in basic science
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Elisabeth Hessmann,1 Steven A Johnsen,2 Jens T Siveke,3,4 Volker Ellenrieder1 1
Department of Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Goettingen, Germany 2 Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, Goettingen, Germany 3 Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany 4 West German Cancer Center, University Hospital Essen, Essen, Germany Correspondence to Professor Volker Ellenrieder, Department of Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Robert-KochStrasse 40, Goettingen 37075, Germany; volker.ellenrieder@ med.uni-goettingen.de Received 30 June 2016 Accepted 30 August 2016 Published Online First 3 November 2016
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most aggressive malignancies with a 5-year survival rate of
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Elisabeth Hessmann,1 Steven A Johnsen,2 Jens T Siveke,3,4 Volker Ellenrieder1 1
Department of Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Goettingen, Germany 2 Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, Goettingen, Germany 3 Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany 4 West German Cancer Center, University Hospital Essen, Essen, Germany Correspondence to Professor Volker Ellenrieder, Department of Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Robert-KochStrasse 40, Goettingen 37075, Germany; volker.ellenrieder@ med.uni-goettingen.de Received 30 June 2016 Accepted 30 August 2016 Published Online First 3 November 2016
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most aggressive malignancies with a 5-year survival rate of
